血小板聚集設備市場- 按產品類型（系統、試劑、消耗品和配件）、應用（研究、臨床[心血管、骨科]）、最終用途（醫院、診斷實驗室、研究機構） - 全球預測，2024 年- 2032 年

在個人化醫療的強勁需求、不斷升級的研發活動和不斷增加的醫療保健支出的推動下，血小板聚集設備市場規模預計在 2024 年至 2032 年期間將以超過 8.9% 的複合年成長率成長。心血管疾病（CVD）仍然是全球死亡的主要原因，對醫療保健系統造成沉重負擔。根據美國心臟病學會的數據，全球心血管疾病死亡人數從1990 年的1240 萬人激增至2022 年的1980 萬人。血管疾病發生率的不斷上升。

血小板聚集裝置在診斷和監測各種心血管疾病（包括血栓形成、心肌梗塞和中風）方面發揮著至關重要的作用。隨著醫療保健提供者努力加強患者護理和改善治療結果，對能夠檢測血小板功能障礙和準確評估血栓風險的先進診斷工具的需求不斷成長。

血小板聚集裝置市場分為產品類型、應用、最終用途和區域。

根據產品類型，試劑領域的行業規模預計從 2024 年到 2032 年將以 8.5% 的複合年成長率成長，因為它們在血小板聚集測試中發揮促進血小板聚集反應檢測和量化的作用。這些試劑包括激動劑，例如二磷酸腺苷 (ADP)、花生四烯酸和膠原蛋白，它們可活化血小板受體並誘導血小板聚集。此外，具有增強特異性和敏感性的新型試劑的開發正在推動血小板聚集設備的創新，使臨床醫生能夠根據個別患者情況量身定做治療方案並最佳化治療結果。

在應用方面，研究領域的血小板聚集設備產業預計到2032年將實現8.6%的複合年成長率。血小板聚集設備的應用鋪平道路。此外，將血小板聚集測試整合到轉化研究和臨床試驗中，有助於識別疾病預後和治療反應的生物標記物，進一步推動該領域的成長。

在快速城市化、人口老化和醫療保健支出增加的推動下，到 2032 年，亞太地區血小板聚集設備產業的複合年成長率預計將達到 10.6%。中國、印度和日本等國家的心血管疾病盛行率激增，進一步推動了先進診斷和監測解決方案的需求。大量患者的存在以及人們對預防性醫療措施的認知不斷增強，也為該地區採用血小板聚集設備創造了有利條件。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 慢性病發生率上升
    • 血小板聚集儀的技術進步
    • 心血管疾病相關患者人數不斷增加
  • 產業陷阱與挑戰
    • 設備成本高，技術人員短缺
• 成長潛力分析
• 監管環境
• 技術景觀
• 波特的分析
• PESTEL分析
• 未來市場趨勢

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按產品類型，2018 年 - 2032 年

• 主要趨勢
• 系統
• 試劑
• 耗材及配件

第 6 章：市場估計與預測：按應用分類，2018 年 - 2032 年

• 主要趨勢
• 研究應用
• 臨床應用
  • 心血管應用
  • 骨科應用
  • 其他臨床應用

第 7 章：市場估計與預測：按最終用途，2018 - 2032 年

• 主要趨勢
• 醫院
• 診斷實驗室
• 研究和學術機構
• 其他最終用戶

第 8 章：市場估計與預測：按地區分類，2018 年 - 2032 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• AggreDyne, Inc.
• Bio/Data Corporation
• Chrono-Log Corporation
• Drucker Diagnostics
• F. Hoffmann-La Roche Ltd.
• Haemonetics Corporation
• Helena Laboratories Corporation
• Siemens Healthineers AG
• Sienco, Inc.
• Sysmex Corporation
• Werfen

Platelet Aggregation Devices Market size is expected to grow at over 8.9% CAGR during 2024-2032, driven by the strong demand for personalized medicine, escalating R&D activities, and increasing healthcare expenditure. Cardiovascular diseases (CVDs) continue to be a leading cause of mortality worldwide, holding a substantial burden on healthcare systems. According to American College of Cardiology, the global death toll from cardiovascular diseases surged from 12.4 million in 1990 to 19.8 million in 2022. Sedentary lifestyles, unhealthy dietary habits, and increasing geriatric population are adding to the escalating incidence of CVDs globally.

Platelet aggregation devices play a crucial role in diagnosing and monitoring various cardiovascular conditions, including thrombosis, myocardial infarction, and stroke. As healthcare providers strive to enhance patient care and improve outcomes, there is a growing demand for advanced diagnostic tools capable of detecting platelet dysfunction and assessing thrombotic risk accurately.

The platelet aggregation devices market is classified into product type, application, end-use and region.

Based on product type, the industry size from the reagents segment is expected to grow at 8.5% CAGR from 2024 to 2032, owing to their role in platelet aggregation testing to facilitate the detection and quantification of platelet aggregation responses. These reagents include agonists, such as adenosine diphosphate (ADP), arachidonic acid, and collagen, which activate platelet receptors and induce platelet aggregation. Furthermore, the development of novel reagents with enhanced specificity and sensitivity is driving innovations in platelet aggregation devices, enabling clinicians to tailor treatment regimens based on individual patient profiles and optimize therapeutic outcomes.

In terms of application, the platelet aggregation devices industry from the research segment is poised to record 8.6% CAGR up to 2032. Researchers are increasingly utilizing platelet aggregation devices to investigate the mechanisms underlying thrombosis, hemostasis, and platelet dysfunction, paving the way for the development of novel therapeutic targets and interventions. Moreover, the integration of platelet aggregation testing into translational research studies and clinical trials is facilitating the identification of biomarkers for disease prognosis and treatment response, further driving the segment growth.

Asia Pacific platelet aggregation devices industry is set to gain traction at 10.6% CAGR till 2032, fueled by rapid urbanization, aging population, and increasing healthcare expenditure. Countries, such as China, India, and Japan are witnessing a surge in the prevalence of cardiovascular diseases, further driving the demand for advanced diagnostic and monitoring solutions. The presence of a large patient pool and growing awareness about preventive healthcare measures are also creating favorable conditions for the adoption of platelet aggregation devices in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of chronic diseases
    • 3.2.1.2 Technological advancements in platelet aggregometers
    • 3.2.1.3 Growing patient population related to cardiovascular diseases
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of devices and shortage of skilled personnel
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis
• 3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Systems
• 5.3 Reagents
• 5.4 Consumables and accessories

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Research applications
• 6.3 Clinical applications
  • 6.3.1 Cardiovascular applications
  • 6.3.2 Orthopedic applications
  • 6.3.3 Other clinical applications

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Diagnostic laboratories
• 7.4 Research and academic institutes
• 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AggreDyne, Inc.
• 9.2 Bio/Data Corporation
• 9.3 Chrono-Log Corporation
• 9.4 Drucker Diagnostics
• 9.5 F. Hoffmann-La Roche Ltd.
• 9.6 Haemonetics Corporation
• 9.7 Helena Laboratories Corporation
• 9.8 Siemens Healthineers AG
• 9.9 Sienco, Inc.
• 9.10 Sysmex Corporation
• 9.11 Werfen